GlassScriptPhysician profile
Timothy Christopher Fermin
NPI 1427391275
$1,705.42
in general payments reported to CMS, 2019-2025
19 companies · $423 in 2025
The $423 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $64.64 · 2021: $65.45 · 2022: $126 · 2023: $287 · 2024: $360 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985 · Debt Forgiveness: $84.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.91 |
| Debt Forgiveness | $84.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.28 | 2019-2025 | Sogroya |
| Abbvie INC. | $239.01 | 2023-2025 | |
| Pfizer INC. | $211.82 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $200.77 | 2023-2025 | Skytrofa |
| Kaleo, INC. | $123.78 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $116.33 | 2019-2025 | Vaxelis, Gardasil, Gardasil 9 |
| Endo USA, INC. | $102.77 | 2024-2025 | Supprelin |
| Baxter Healthcare | $84.73 | 2025 | |
| Ferring Pharmaceuticals INC. | $65.95 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $58.64 | 2023-2024 | Supprelin |
| Biomarin Pharmaceutical INC. | $44.14 | 2022-2023 | Voxzogo 1.2mg |
| Takeda Pharmaceuticals U.S.A., INC. | $24.17 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.15 | 2025 | |
| Incyte Corporation | $21.16 | 2021 | |
| Sanofi Pasteur INC. | $20.46 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $20.05 | 2025 | Zoryve |
| Ars Pharmaceuticals Operations, INC. | $20.02 | 2025 | Neffy |
| Alk-Abello, INC | $14.99 | 2025 | Neffy |
| Aytu Biopharma, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Fermin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.